Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia (original) (raw)

• Raimundo, N., Baysal, B.E. & Shadel, G.S. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol. Med. 17, 641–649 (2011).
  Article CAS Google Scholar
• Mardis, E.R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058–1066 (2009).
  Article CAS Google Scholar
• Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).
  Article CAS Google Scholar
• Gross, S. et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339–344 (2010).
  Article CAS Google Scholar
• Parsons, D.W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 (2008).
  Article CAS Google Scholar
• Patel, J.P. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079–1089 (2012).
  Article CAS Google Scholar
• Ward, P.S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).
  Article CAS Google Scholar
• Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).
  Article CAS Google Scholar
• Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate–dependent dioxygenases. Cancer Cell 19, 17–30 (2011).
  Article CAS Google Scholar
• Figueroa, M.E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).
  Article CAS Google Scholar
• Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474–478 (2012).
  Article CAS Google Scholar
• Shlush, L.I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328–333 (2014).
  Article CAS Google Scholar
• Corces-Zimmerman, M.R., Hong, W.J., Weissman, I.L., Medeiros, B.C. & Majeti, R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl. Acad. Sci. USA 111, 2548–2553 (2014).
  Article CAS Google Scholar
• Chan, S.M. & Majeti, R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int. J. Hematol. 98, 648–657 (2013).
  Article CAS Google Scholar
• Jan, M. et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 4, 149ra118 (2012).
  Article Google Scholar
• Chou, W.C. et al. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 25, 246–253 (2011).
  Article CAS Google Scholar
• Chou, W.C. et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 115, 2749–2754 (2010).
  Article CAS Google Scholar
• Wang, F. et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340, 622–626 (2013).
  Article CAS Google Scholar
• Rohle, D. et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626–630 (2013).
  Article CAS Google Scholar
• Luo, J., Solimini, N.L. & Elledge, S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823–837 (2009).
  Article CAS Google Scholar
• Souers, A.J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202–208 (2013).
  Article CAS Google Scholar
• Pan, R. et al. Selective BCL-2 inhibition by ABT-199 causes on target cell death in acute myeloid leukemia. Cancer Discov. 4, 362–375 (2014).
  Article CAS Google Scholar
• BCL-2 inhibitor yields high response in CLL and SLL. Cancer Discov. 4, OF5 (2014).
• Dick, J.E. Stem cell concepts renew cancer research. Blood 112, 4793–4807 (2008).
  Article CAS Google Scholar
• Saito, Y. et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 28, 275–280 (2010).
  Article CAS Google Scholar
• Craddock, C. et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 27, 1028–1036 (2013).
  Article CAS Google Scholar
• Ni Chonghaile, T. & Letai, A. Mimicking the BH3 domain to kill cancer cells. Oncogene 27 (suppl. 1), S149–S157 (2008).
  Article Google Scholar
• Ryan, J. & Letai, A. BH3 profiling in whole cells by fluorimeter or FACS. Methods 61, 156–164 (2013).
  Article CAS Google Scholar
• Danial, N.N. BAD: undertaker by night, candyman by day. Oncogene 27 (suppl. 1), S53–S70 (2008).
  Article CAS Google Scholar
• Ploner, C., Kofler, R. & Villunger, A. Noxa: at the tip of the balance between life and death. Oncogene 27 (suppl. 1), S84–S92 (2008).
  Article CAS Google Scholar
• Glaser, S.P. et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 26, 120–125 (2012).
  Article CAS Google Scholar
• Shi, J. et al. An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation. Neurol. Sci. 35, 839–845 (2014).
  Article Google Scholar
• Mohrenz, I.V. et al. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis 18, 1416–1425 (2013).
  Article CAS Google Scholar
• Hockenbery, D.M., Oltvai, Z.N., Yin, X.M., Milliman, C.L. & Korsmeyer, S.J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75, 241–251 (1993).
  Article CAS Google Scholar
• da Silva, C.G. et al. Inhibition of cytochrome c oxidase activity in rat cerebral cortex and human skeletal muscle by D-2-hydroxyglutaric acid in vitro. Biochim. Biophys. Acta 1586, 81–91 (2002).
  Article CAS Google Scholar
• Latini, A. et al. Mitochondrial energy metabolism is markedly impaired by D-2-hydroxyglutaric acid in rat tissues. Mol. Genet. Metab. 86, 188–199 (2005).
  Article CAS Google Scholar
• Wajne, M. et al. d-2-Hydroxyglutaric aciduria in a patient with a severe clinical phenotype and unusual MRI findings. J. Inherit. Metab. Dis. 25, 28–34 (2002).
  Article CAS Google Scholar
• Rohlena, J., Dong, L.F. & Neuzil, J. Targeting the mitochondrial electron transport chain complexes for the induction of apoptosis and cancer treatment. Curr. Pharm. Biotechnol. 14, 377–389 (2013).
  Article CAS Google Scholar
• Rohlena, J., Dong, L.F., Ralph, S.J. & Neuzil, J. Anticancer drugs targeting the mitochondrial electron transport chain. Antioxid. Redox Signal. 15, 2951–2974 (2011).
  Article CAS Google Scholar
• Grassian, A.R. et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res. 74, 3317–3331 (2014).
  Article CAS Google Scholar
• Choi, C. et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat. Med. 18, 624–629 (2012).
  Article CAS Google Scholar
• Kölker, S. et al. NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in D-2-hydroxyglutaric aciduria. Eur. J. Neurosci. 16, 21–28 (2002).
  Article Google Scholar
• Capaldi, R.A. Structure and function of cytochrome c oxidase. Annu. Rev. Biochem. 59, 569–596 (1990).
  Article CAS Google Scholar
• Sherman, D., Kotake, S., Ishibe, N. & Copeland, R.A. Resolution of the electronic transitions of cytochrome c oxidase: evidence for two conformational states of ferrous cytochrome α. Proc. Natl. Acad. Sci. USA 88, 4265–4269 (1991).
  Article CAS Google Scholar
• Nicholls, P. & Hildebrandt, V. Binding of ligands and spectral shifts in cytochrome c oxidase. Biochem. J. 173, 65–72 (1978).
  Article CAS Google Scholar
• Yoshikawa, S., Mochizuki, M., Zhao, X.J. & Caughey, W.S. Effects of overall oxidation state on infrared spectra of heme a3 cyanide in bovine heart cytochrome c oxidase. Evidence of novel mechanistic roles for CuB. J. Biol. Chem. 270, 4270–4279 (1995).
  Article CAS Google Scholar
• Way, J.L. Cyanide intoxication and its mechanism of antagonism. Annu. Rev. Pharmacol. Toxicol. 24, 451–481 (1984).
  Article CAS Google Scholar
• Koivunen, P. et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483, 484–488 (2012).
  Article CAS Google Scholar
• Li, Y., Park, J.S., Deng, J.H. & Bai, Y. Cytochrome c oxidase subunit IV is essential for assembly and respiratory function of the enzyme complex. J. Bioenerg. Biomembr. 38, 283–291 (2006).
  Article CAS Google Scholar
• Skrtić, M. et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20, 674–688 (2011).
  Article Google Scholar
• McClintock, D.S. et al. Bcl-2 family members and functional electron transport chain regulate oxygen deprivation-induced cell death. Mol. Cell. Biol. 22, 94–104 (2002).
  Article CAS Google Scholar
• Saikumar, P. et al. Role of hypoxia-induced Bax translocation and cytochrome c release in reoxygenation injury. Oncogene 17, 3401–3415 (1998).
  Article CAS Google Scholar
• Hetschko, H. et al. BH3 mimetics reactivate autophagic cell death in anoxia-resistant malignant glioma cells. Neoplasia 10, 873–885 (2008).
  Article CAS Google Scholar
• Shimizu, S. et al. Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature 374, 811–813 (1995).
  Article CAS Google Scholar
• Shroff, E.H., Snyder, C. & Chandel, N.S. Role of Bcl-2 family members in anoxia induced cell death. Cell Cycle 6, 807–809 (2007).
  Article CAS Google Scholar
• Silkjaer, T. et al. Characterization and prognostic significance of mitochondrial DNA variations in acute myeloid leukemia. Eur. J. Haematol. 90, 385–396 (2013).
  Article CAS Google Scholar
• Larman, T.C. et al. Spectrum of somatic mitochondrial mutations in five cancers. Proc. Natl. Acad. Sci. USA 109, 14087–14091 (2012).
  Article CAS Google Scholar
• Vo, T.T. et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151, 344–355 (2012).
  Article CAS Google Scholar
• Konopleva, M. et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10, 375–388 (2006).
  Article CAS Google Scholar
• Lagadinou, E.D. et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329–341 (2013).
  Article CAS Google Scholar
• Xu, Q., Thompson, J.E. & Carroll, M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 106, 4261–4268 (2005).
  Article CAS Google Scholar
• von Bonin, M. et al. In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice. PLoS ONE 8, e60680 (2013).
  Article CAS Google Scholar
• Ryan, J. & Letai, A. BH3 profiling in whole cells by fluorimeter or FACS. Methods 61, 156–164 (2013).
  Article CAS Google Scholar
• Chen, J. et al. The Bcl-2/Bcl-XL/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol. Cancer Ther. 10, 2340–2349 (2011).
  Article CAS Google Scholar
• Ward, P.S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).
  Article CAS Google Scholar